Business

Announcement on Voluntary Disclosure of Initiation of Phase II/III Clinical Trial for Diphtheria, Tetanus and Acellular Pertussis (Component) Combined Vaccine, Adsorbed (for Population Aged 6 and Above) and Completion of First Subject Enrollment in Phase II Clinical Trial

Announcement on Voluntary Disclosure of Initiation of Phase II/III Clinical Trial for Diphtheria, Tetanus and Acellular Pertussis (Component) Combined Vaccine, Adsorbed (for Population Aged 6 and Above) and Completion of First Subject Enrollment in Phase II Clinical Trial

articleCansino Biologics, Inc. Class ADecember 20, 20245/news/announcement-on-voluntary-disclosure-of-initiation-of-phase-iiiii-clinical-trial-for-diphtheria-tetanus-and-acellular-pertussis-component-combined-vaccine-adsorbed-for-population-aged-6-and-above-and-completion-of-first-subject-enrollment-in-phase-ii-clinical-trial
Announcement on Voluntary Disclosure of Initiation of Phase II/III Clinical Trial for Diphtheria, Tetanus and Acellular Pertussis (Component) Combined Vaccine, Adsorbed (for Population Aged 6 and Above) and Completion of First Subject Enrollment in Phase II Clinical Trial

About this update from Cansino Biologics, Inc. Class A

Announcement on Voluntary Disclosure of Initiation of Phase II/III Clinical Trial for Diphtheria, Tetanus and Acellular Pertussis (Component) Combined Vaccine, Adsorbed (for Population Aged 6 and Above) and Completion of First Subject Enrollment in Phase II Clinical TrialThe abstract is for reference only. Please refer to the full text of the announcement on the very day.Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Cansino Biologics, Inc. Class A